A Phase II/III, Randomized, Open Label, Controlled, Two Arm Study Comparing Overall Survival of AlloStim Combined With Cryoablation to a Physician's Choice Combined With Cryoablation in 3rd Line Treatment for Metastatic Colorectal Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II/III

Latest Information Update: 07 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs T-cell vaccine-AlloStim (Primary) ; T-cell vaccine-AlloStim (Primary)
Indications Colorectal cancer
Focus Therapeutic Use
Sponsors Immunovative Therapies

Most Recent Events

17 Jan 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
07 Aug 2016 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020.
07 Aug 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight